A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients: Risk-reducing salpingo-oophorectomy in BRCA mutations

Vera Loizzi; Ettore Cicinelli; Vittoria Del Vecchio; Francesca Arezzo; Xheni  Deromemaj; Anila Kardhashi; Angelo Paradiso; Francesco Legge; Maria Iole  Natalicchio; Leonardo Resta; Nicoletta Resta; Daria Carmela Loconte; Gennaro Cormio

doi:10.23750/abm.v93i4.11695

A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients

Risk-reducing salpingo-oophorectomy in BRCA mutations

Authors

Vera Loizzi Obstetrics and Gynecology Unit, DIM Department, University of Bari, Italy
Ettore Cicinelli Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy
Vittoria Del Vecchio Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy
Francesca Arezzo a:1:{s:5:"en_US";s:116:"Department of Biomedical Sciences and Human Oncology, University of Bari, Italy Piazza Giulio Cesare 11, Bari Italy ";}
Xheni Deromemaj Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy
Anila Kardhashi Gynecology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy
Angelo Paradiso Institutional BioBank, Experimental Oncology and Biobank Management Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
Francesco Legge Gynecologic Oncology Unit, General Regional Hospital “F. Miulli” of Acquaviva delle Fonti, Italy
Maria Iole Natalicchio Molecular Oncology and Pharmacogenomics laboratory, University of Foggia, Italy
Leonardo Resta Department of Pathology, University of Bari, Italy.
Nicoletta Resta Medical Genetics Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy
Daria Carmela Loconte Medical Genetics Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy
Gennaro Cormio Obstetrics and Gynecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari, Italy

DOI: https://doi.org/10.23750/abm.v93i4.11695

Keywords:

BRCA, ovarian cancer, risk-reducing surgery, genetical screening, cancer prevention

Abstract

Background and aim of the work: BRCA1/2 are tumour-suppressor genes involved in DNA homologous recombination and ovarian cancer development. The study evaluated the risk of tumor cancer in women presenting the BRCA mutations.

Methods: Risk-reducing surgery (RRS) was performed in 100 patients carrying BRCA1 (aged between 30-73 years, median age was 51 years) and BRCA 2 mutation (aged between 36-70 years, median age was 53 years). Fifty-eight patients had previous history of breast cancer.

Results: Between the 100 patients, 82 women underwent risk-reducing salpingo-oophorectomy (RRSO) through a laparoscopic minimally invasive approach, 7 (7 %) underwent laparoscopic RRSO and contextual hysterectomy, 1 woman (1 %) underwent RRSO through a laparotomic approach and 10 women (10 %) laparotomic RRSO and hysterectomy. During 5 (5 %) laparoscopic RRSO, prophylactic bilateral mastectomy was also performed. Early and late complication occurred in 3 patients (3 %). Two patients (2 %) were found to have occult Serous Tubal Intraepithelial Carcinoma (STIC) and three patients (3 %) occult cancer.

Conclusions: RRSO is safe and feasible in BRCA mutation carriers. The procedure is effective for genetic prevention of ovarian cancer.

References

[1] Angela Toss, Chiara Tomasello, Elisabetta Razzaboni, et al. Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes, Biomed Res Int. 2015; 2015: 341723.
[2] Temkin SM, Bergstrom J, Samimi G, Minasian L. Ovarian Cancer Prevention in High-risk Women., Clin Obstet Gynecol. 2017 Dec;60(4):738-757. doi:10.1097/GRF.0000000000000318
[3] Bogani G, Tagliabue E, Signorelli M, et al. Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience., J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):837-842. doi: 10.1016/j.jmig.2017.04.017. Epub 2017 May 4.
[4] Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS. Surgical prevention strategies in ovarian cancer. Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4.
[5] Lee YJ, Lee SW, Kim KR, Jung KH, Lee JW, Kim YM. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers., J Gynecol Oncol. 2017 Jan;28(1):e3.
[6] Loizzi V, Cicinelli E, Santamaria F, et al. BRCAmut and "founder effect": a prospective study in a single academic institution., Oncotarget. 2018 Apr 27;9(32):22353-22358.
[7] Mau C, Untch M. Prophylactic Surgery: For Whom, When and How?, Breast Care (Basel). 2017 Dec;12(6):379-384.
[8] Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, et al. Hereditary Breast and Ovarian Cancer Research Group Netherlands., Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction., J Natl Cancer Inst. 2015 Mar 18;107(5). pii: djv033.
[9] Nasim Mavaddat, Paul D. P. Pharoah, Kyriaki Michailidou, et al. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants, J Natl Cancer Inst. 2015 May; 107(5): djv036.
[10] Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer., JAMA. 2015 Apr 7;313(13):1347-61.
[11] Joan L. Walker , C. Bethan Powell ,Lee‐may Chen , et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. 2015.
[12] Finch A., Chiang JK, Elit L, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation, Gynecol Oncol. 2011 Apr;121(1):163-8.
[13] NCCN Guidelines Version 3.2019, BRCA-Related Breast and/or Ovarian Cancer Syndrome.
[14] Soong TR, Kolin DL, Teschan NJ, Crum CP. Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis., Cancers (Basel). 2018 Nov 28;10 (12). pii: E468.
[15] Lee EG, Kang HJ, Lim MC, et al. Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers, Cancer Res Treat. 2019 Jan;51(1):280-288.
[16] Sherman ME, Piedmonte M, Mai PL, et al. Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199, J Clin Oncol. 2014 Oct 10; 32(29): 3275–3283.
[17] Finch APM , Lubinski J, Møller P , et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol. 2014 May 20;32(15):1547-53.
[18] Faubion S.S., Kuhle C.L., Shuster L.T., Rocca W.A. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015;18:483–491.
[19] European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. Webber L., de Muinck Keizer-Schrama S., Hogervorst E., Davies M., Anderson R., Bartlett J., Braat D., Cartwright B., Cifkova R., et al. ESHRE Guideline: Management of women with premature ovarian insufficiency. Hum. Reprod. 2016;31:926–937.
[20] Kotsopoulos J., Gronwald J., Karlan B.Y., Huzarski T., Tung N., Moller P., Armel S., Lynch H.T., Senter L., Eisen A., et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol. 2018;4:1059–1065.
[21] Smith D.C., Prentice R., Thompson D.J., Herrmann W.L. Association of exogenous estrogen and endometrial carcinoma. N. Engl. J. Med. 1975;293:1164–1167.
[22] Luisi S., Orlandini C., Regini C., Pizzo A., Vellucci F., Petraglia F. Premature ovarian insufficiency: From pathogenesis to clinical management. J. Endocrinol. Investig. 2015;38:597–603.